Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for recurrent fibrosis prevention in HCV liver transplant
NCT01603108Phase 2Unknown
- Sponsor
- Columbia University
- Start
- Mar 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in hepatitis C (HCV), sponsored by Columbia University. Primary endpoint: Significant recurrence of Hepatitis C at 1 year. Status: unknown.
02
Drugs
rifaximin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01603108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01603108.